MCID: GLC086
MIFTS: 46

Glucocorticoid-Induced Osteoporosis

Categories: Bone diseases

Aliases & Classifications for Glucocorticoid-Induced Osteoporosis

MalaCards integrated aliases for Glucocorticoid-Induced Osteoporosis:

Name: Glucocorticoid-Induced Osteoporosis 12 15
Steroid-Induced Osteoporosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060343

Summaries for Glucocorticoid-Induced Osteoporosis

Disease Ontology : 12 An osteoporosis caused by chronic glucocorticoid use. Glucocorticoids impair the replication, differentiation and function of osteoblasts and induce the apoptosis of mature osteoblasts and osteocytes; the also favor osteoclastogenesis leading to an increase in bone resorption.

MalaCards based summary : Glucocorticoid-Induced Osteoporosis, also known as steroid-induced osteoporosis, is related to periodontitis and osteoporosis. An important gene associated with Glucocorticoid-Induced Osteoporosis is BGLAP (Bone Gamma-Carboxyglutamate Protein), and among its related pathways/superpathways are Wnt Signaling Pathways: beta-Catenin-dependent Wnt Signaling and Osteoclast differentiation. The drugs Denosumab and Teriparatide have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and lung, and related phenotypes are growth/size/body region and craniofacial

Wikipedia : 76 Steroid-induced osteoporosis (SIOP) is osteoporosis arising due to use of glucocorticoids (steroid... more...

Related Diseases for Glucocorticoid-Induced Osteoporosis

Diseases related to Glucocorticoid-Induced Osteoporosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 106)
# Related Disease Score Top Affiliating Genes
1 periodontitis 30.0 BGLAP RUNX2 TNFRSF11B TNFSF11
2 osteoporosis 29.8 ACP5 BGLAP BMP2 CALCA DKK1 IGF1
3 osteomyelitis 29.5 ACP5 BMP2 TNFSF11
4 osteonecrosis 28.9 ACP5 BGLAP BMP2 PTH RUNX2 TNFRSF11B
5 bone disease 28.5 ACP5 BGLAP CALCA DKK1 IGF1 PTH
6 bone resorption disease 28.3 ACP5 BGLAP BMP2 CALCA DKK1 IGF1
7 bone mineral density quantitative trait locus 8 10.5
8 bone mineral density quantitative trait locus 15 10.5
9 arthritis 10.4
10 rheumatoid arthritis 10.4
11 autoimmune disease 10.2
12 conn's syndrome 10.2
13 nontoxic goiter 10.2 BGLAP CALCA
14 polyarticular onset juvenile idiopathic arthritis 10.2 TNFRSF11B TNFSF11
15 hemophilic arthropathy 10.2 TNFRSF11B TNFSF11
16 aneurysmal bone cysts 10.2 CALCA TNFSF11
17 multicentric reticulohistiocytosis 10.2 TNFRSF11B TNFSF11
18 periodontitis, chronic 10.2 TNFRSF11B TNFSF11
19 chronic apical periodontitis 10.2 TNFRSF11B TNFSF11
20 familial expansile osteolysis 10.2 TNFRSF11B TNFSF11
21 autoimmune disease 1 10.2
22 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
23 inflammatory bowel disease 10.2
24 axial osteomalacia 10.2 BGLAP PTH
25 extraskeletal chondroma 10.2 BGLAP PTH
26 hypercalcemia, infantile, 1 10.2 CALCA PTH
27 idiopathic hypercalciuria 10.1 BGLAP TNFSF11
28 impaired renal function disease 10.1 BGLAP PTH
29 joint disorders 10.1 DKK1 TNFSF11
30 cloacogenic carcinoma 10.1 CALCA PTH
31 alveolar periostitis 10.1 BGLAP RUNX2
32 metaphyseal chondrodysplasia, jansen type 10.1 CALCA PTH
33 paget disease of bone 5, juvenile-onset 10.1 CALCA TNFRSF11B TNFSF11
34 carcinoid syndrome 10.1 CALCA IGF1
35 multicentric carpotarsal osteolysis syndrome 10.1 BGLAP TNFRSF11B TNFSF11
36 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 10.1
37 asthma 10.1
38 amenorrhea 10.1
39 kummell's disease 10.1 DKK1 TNFRSF11B TNFSF11
40 osteitis fibrosa 10.1 BGLAP CALCA PTH
41 pseudohypoparathyroidism, type ib 10.1 BGLAP PTH
42 villonodular synovitis 10.1 ACP5 TNFSF11
43 fibrogenesis imperfecta ossium 10.1 CALCA PTH TNFRSF11B
44 hypophosphatasia, adult 10.1 BGLAP CALCA PTH
45 parathyroid gland disease 10.1 BGLAP CALCA PTH
46 osteomalacia 10.1 BGLAP CALCA PTH
47 pseudohypoparathyroidism 10.1 BGLAP PTH
48 camurati-engelmann disease 10.1 ACP5 BGLAP
49 parathyroid adenoma 10.1 BGLAP CALCA PTH
50 trichorhinophalangeal syndrome, type i 10.1 RUNX2 TNFRSF11B

Graphical network of the top 20 diseases related to Glucocorticoid-Induced Osteoporosis:



Diseases related to Glucocorticoid-Induced Osteoporosis

Symptoms & Phenotypes for Glucocorticoid-Induced Osteoporosis

MGI Mouse Phenotypes related to Glucocorticoid-Induced Osteoporosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.92 BMP2 DKK1 IGF1 PTH RUNX2 SFRP1
2 craniofacial MP:0005382 9.91 BMP2 DKK1 PTH RUNX2 SFRP1 TNFRSF11B
3 hematopoietic system MP:0005397 9.8 BMP2 IGF1 PTH RUNX2 SFRP1 TNFRSF11B
4 immune system MP:0005387 9.7 BMP2 IGF1 PTH RUNX2 SFRP1 TNFRSF11B
5 limbs/digits/tail MP:0005371 9.56 BMP2 DKK1 IGF1 PTH RUNX2 SFRP1
6 skeleton MP:0005390 9.23 BMP2 DKK1 IGF1 PTH RUNX2 SFRP1

Drugs & Therapeutics for Glucocorticoid-Induced Osteoporosis

Drugs for Glucocorticoid-Induced Osteoporosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denosumab Approved Phase 4,Phase 3,Phase 1,Phase 2 615258-40-7
2
Teriparatide Approved, Investigational Phase 4,Phase 3,Phase 2 52232-67-4 16133850
3
Etidronic acid Approved Phase 4,Phase 3 7414-83-7, 2809-21-4 3305
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Alendronate Approved Phase 4,Phase 3,Phase 2 66376-36-1, 121268-17-5 2088
6 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Calcium, Dietary Phase 4,Phase 3,Phase 2,Not Applicable
12 Ibandronic acid Phase 4
13 Diphosphonates Phase 4
14 Risedronate Sodium Phase 4,Phase 3 115436-72-1
15 calcium channel blockers Phase 4,Phase 3
16
Alfacalcidol Approved, Nutraceutical Phase 3,Not Applicable 41294-56-8 5282181
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 1406-16-2
18
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3,Phase 3 67-97-0 5280795 6221
19
Genistein Investigational Phase 2, Phase 3 446-72-0 5280961
20 Hydroxycholecalciferols Phase 3,Not Applicable
21 Vitamins Phase 3,Phase 2,Not Applicable
22 Micronutrients Phase 3,Phase 2,Not Applicable
23 Trace Elements Phase 3,Phase 2,Not Applicable
24 Estrogens Phase 2, Phase 3,Not Applicable
25 Calciferol Phase 3,Phase 2
26 Protein Kinase Inhibitors Phase 2, Phase 3
27 Protective Agents Phase 2, Phase 3
28 Phytoestrogens Phase 2, Phase 3
29
Methylprednisolone Approved, Vet_approved 83-43-2 6741
30
Prednisolone Approved, Vet_approved 50-24-8 5755
31
Prednisolone phosphate Approved, Vet_approved 302-25-0
32
Methylprednisolone hemisuccinate Approved 2921-57-5
33
Tramadol Approved, Investigational 27203-92-5 33741
34
Morphine Approved, Investigational 57-27-2 5288826
35
Calcitriol Approved, Nutraceutical Not Applicable 32222-06-3 5280453 134070
36
Prednisolone hemisuccinate Experimental 2920-86-7
37 Vasoconstrictor Agents Not Applicable
38 Estrogen Antagonists Not Applicable
39 Estrogen Receptor Modulators Not Applicable
40 Selective Estrogen Receptor Modulators Not Applicable
41 Estrogen Receptor Antagonists Not Applicable
42 Raloxifene Hydrochloride Not Applicable
43 Peripheral Nervous System Agents
44 Autonomic Agents
45 Neuroprotective Agents
46 Methylprednisolone acetate
47 Anti-Inflammatory Agents
48 Prednisolone acetate
49 Antiemetics
50 Gastrointestinal Agents

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis. Completed NCT00545051 Phase 4 Placebo;ibandronate
2 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
3 Efficacy of Monthly Ibandronate in Women With RA and Reduced Bone Mineral Density Receiving Long-term Steroids Completed NCT01287533 Phase 4 Ibandronate;Placebo
4 Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use Completed NCT00221299 Phase 4 Risedronate;Parathyroid Hormone
5 HRT Versus Etidronate for Osteoporosis and Fractures in Asthmatics Receiving Glucocorticoids. Completed NCT00376662 Phase 4 Hormone Replacement Therapy and Etidronate
6 Denosumab Versus Bisphosphonates (Alendronate) in GIOP Recruiting NCT03005678 Phase 4 Denosumab;Alendronate
7 Zoledronic Acid in Cystic Fibrosis Withdrawn NCT01702415 Phase 4 Zoledronic acid;Placebo
8 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
9 Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis Completed NCT00503399 Phase 3 Teriparatide;Risedronate
10 Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis Completed NCT00051558 Phase 3 Teriparatide;Alendronate Sodium;Placebo;Placebo
11 Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids Completed NCT01575873 Phase 3 Denosumab;Placebo for risendronate;Risendronate;Placebo for denosumab
12 Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis Recruiting NCT03164928 Phase 3 Denosumab
13 Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis Recruiting NCT03040531 Phase 2, Phase 3 Alendronate Oral Tablet
14 Can Parathyroid Hormone Injections Reverse Glucocorticoid-induced Osteoporosis Completed NCT00004993 Phase 2 Parathyroid hormone (hPTH 1-34)
15 Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women Active, not recruiting NCT01440803 Phase 2 Teriparatide;Saline Placebo
16 Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders Not yet recruiting NCT02418273 Phase 1, Phase 2 denosumab
17 Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol Unknown status NCT01974167 Not Applicable Eldecalcitol;Alfacalcidol
18 Clinical Trial on the Efficacy of Raloxifene on Disease Activity in Rheumatoid Arthritis Unknown status NCT02982083 Not Applicable Raloxifene hydrochloride;Placebo Oral Tablet
19 GIOP Prevention Among People With Rheumatoid Arthritis Completed NCT00609830 Not Applicable
20 Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis Recruiting NCT02719314 Glucocorticoid treatment
21 Study of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders Recruiting NCT02252679
22 Percutaneous Vertebroplasty Versus Conservative Treatment in GIOPVCF Not yet recruiting NCT03330340

Search NIH Clinical Center for Glucocorticoid-Induced Osteoporosis

Genetic Tests for Glucocorticoid-Induced Osteoporosis

Anatomical Context for Glucocorticoid-Induced Osteoporosis

MalaCards organs/tissues related to Glucocorticoid-Induced Osteoporosis:

41
Bone, Kidney, Lung, Heart, Adipocyte, Thyroid, T Cells

Publications for Glucocorticoid-Induced Osteoporosis

Articles related to Glucocorticoid-Induced Osteoporosis:

(show top 50) (show all 512)
# Title Authors Year
1
Effects of quality indicator monitoring for glucocorticoid-induced osteoporosis and trends of drug treatment in a Japanese hospital. ( 29878618 )
2018
2
Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis. ( 29557941 )
2018
3
Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. ( 29251033 )
2018
4
Myricetin ameliorates glucocorticoid-induced osteoporosis through the ERK signaling pathway. ( 29883721 )
2018
5
Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. ( 29904824 )
2018
6
Gastrodin alleviates glucocorticoid induced osteoporosis in rats via activating the Nrf2 signaling pathways. ( 29545917 )
2018
7
The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial. ( 29543887 )
2018
8
Glucocorticoid-Induced Osteoporosis: Management Challenges in Older Patients. ( 29941355 )
2018
9
Glucocorticoid-induced osteoporosis: an update. ( 29691807 )
2018
10
Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice. ( 29800693 )
2018
11
Epigallocatechin-3-Gallate Ameliorates Glucocorticoid-Induced Osteoporosis of Rats <i>in Vivo</i> and <i>in Vitro</i>. ( 29867459 )
2018
12
Just the FRAX: Management ofA Glucocorticoid-Induced Osteoporosis. ( 29337149 )
2018
13
Autophagy as a target for glucocorticoid-induced osteoporosis therapy. ( 29427075 )
2018
14
Role of Teriparatide in Glucocorticoid-induced Osteoporosis through Regulating Cellular Reactive Oxygen Species. ( 29745033 )
2018
15
Intramembranous ossification and endochondral ossification are impaired differently between glucocorticoid-induced osteoporosis and estrogen deficiency-induced osteoporosis. ( 29497100 )
2018
16
Denosumab: a new treatment option for glucocorticoid-induced osteoporosis. ( 29631783 )
2018
17
Efficacy of Denosumab for Glucocorticoid-Induced Osteoporosis in an Adolescent Patient with Duchenne Muscular Dystrophy: A Case Report. ( 29642113 )
2018
18
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. ( 29631782 )
2018
19
Prevention of Glucocorticoid-Induced Osteoporosis: Clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting. ( 29729949 )
2018
20
Pro-inflammatory cytokines: cellular and molecular drug targets for glucocorticoid-induced-osteoporosis via osteocyte. ( 29618305 )
2018
21
Denosumab for glucocorticoid-induced osteoporosis. ( 29849116 )
2018
22
Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia. ( 29105349 )
2018
23
Multiple vertebral fractures associated with glucocorticoid-induced osteoporosis treated with teriparatide followed by kyphosis correction fusion: a case report. ( 29476202 )
2018
24
The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis. ( 29607978 )
2018
25
The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial. ( 29729427 )
2018
26
GAG and collagen II attenuate glucocorticoid-induced osteoporosis by regulating NF-κB and MAPK signaling. ( 30018717 )
2018
27
Denosumab in the treatment of glucocorticoid-induced osteoporosis. ( 30019224 )
2018
28
Morin protects glucocorticoid-induced osteoporosis through regulating the mitogen-activated protein kinase signaling pathway. ( 30043216 )
2018
29
Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs. ( 30187273 )
2018
30
Luteolin attenuates glucocorticoid-induced osteoporosis by regulating ERK/Lrp-5/GSK-3β signaling pathway in vivo and in vitro. ( 30192012 )
2018
31
Ptychographic X-ray CT characterization of the osteocyte lacuno-canalicular network in a male rat's glucocorticoid induced osteoporosis model. ( 30246062 )
2018
32
Combined treatment with cinnamaldehyde and PTH enhances the therapeutic effect on glucocorticoid-induced osteoporosis through inhibiting osteoclastogenesis and promoting osteoblastogenesis. ( 30309646 )
2018
33
Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: A meta-analysis of randomized controlled trials. ( 30334952 )
2018
34
Technetium-99 Conjugated with Methylene Diphosphonate Ameliorates Glucocorticoid Induced Osteoporosis by Inhibiting Osteoclastogenesis. ( 30406140 )
2018
35
Osteoblast autophagy in glucocorticoid-induced osteoporosis. ( 30417506 )
2018
36
Celastrol inhibits glucocorticoid‑induced osteoporosis in rat via the PI3K/AKT and Wnt signaling pathways. ( 30221712 )
2018
37
Bone matrix development in steroid-induced osteoporosis is associated with a consistently reduced fibrillar stiffness linked to altered bone mineral quality. ( 29902593 )
2018
38
Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis. ( 26929019 )
2018
39
Adenosine Receptor Stimulation Improves Glucocorticoid-Induced Osteoporosis in a Rat Model. ( 28928654 )
2017
40
Adrenomedullin inhibits osteoclast differentiation through the suppression of receptor activator of nuclear factor-I_B ligand-induced nuclear factor-I_B activation in glucocorticoid-induced osteoporosis. ( 29067096 )
2017
41
Effects of glucocorticoid-induced osteoporosis on bone tissue of rats with experimental periodontitis. ( 28178585 )
2017
42
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. ( 28585410 )
2017
43
Bone: Towards a better management of glucocorticoid-induced osteoporosis? ( 28855696 )
2017
44
Targeting osteoblastic casein kinase-2 interacting protein-1 to enhance Smad-dependent BMP signaling and reverse bone formation reduction in glucocorticoid-induced osteoporosis. ( 28128304 )
2017
45
Effects of 1,25-dihydroxyvitamin D3 on the local bone renin-angiotensin system in a murine model of glucocorticoid-induced osteoporosis. ( 28587403 )
2017
46
Comment on 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. ( 28941168 )
2017
47
Low Doses of Simvastatin Potentiate the Effect of Sodium Alendronate in Inhibiting Bone Resorption and Restore Microstructural and Mechanical Bone Properties in Glucocorticoid-Induced Osteoporosis. ( 28743325 )
2017
48
Glucocorticoid-induced Osteoporosis. ( 28989868 )
2017
49
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. ( 28941179 )
2017
50
Prevalence and risk factors associated with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis. ( 28374332 )
2017

Variations for Glucocorticoid-Induced Osteoporosis

Expression for Glucocorticoid-Induced Osteoporosis

Search GEO for disease gene expression data for Glucocorticoid-Induced Osteoporosis.

Pathways for Glucocorticoid-Induced Osteoporosis

GO Terms for Glucocorticoid-Induced Osteoporosis

Cellular components related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 BGLAP BMP2 CALCA DKK1 IGF1 PTH
2 extracellular space GO:0005615 9.28 BGLAP BMP2 CALCA DKK1 IGF1 PTH

Biological processes related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.96 BMP2 IGF1 RUNX2 SFRP1
2 negative regulation of transcription, DNA-templated GO:0045892 9.95 BMP2 CALCA RUNX2 SFRP1
3 response to drug GO:0042493 9.87 BGLAP PTH SFRP1 TNFRSF11B
4 negative regulation of gene expression GO:0010629 9.85 BMP2 IGF1 SFRP1
5 cell-cell signaling GO:0007267 9.84 BMP2 CALCA PTH
6 positive regulation of gene expression GO:0010628 9.83 BMP2 DKK1 IGF1 RUNX2 TNFSF11
7 negative regulation of canonical Wnt signaling pathway GO:0090090 9.79 BMP2 DKK1 SFRP1
8 positive regulation of osteoblast differentiation GO:0045669 9.69 BMP2 IGF1 RUNX2
9 monocyte chemotaxis GO:0002548 9.68 CALCA TNFSF11
10 chondrocyte differentiation GO:0002062 9.67 BMP2 RUNX2
11 positive regulation of Wnt signaling pathway GO:0030177 9.67 BMP2 SFRP1
12 cellular response to growth factor stimulus GO:0071363 9.67 BGLAP BMP2 SFRP1
13 positive regulation of bone mineralization GO:0030501 9.65 BMP2 PTH
14 positive regulation of glucose import GO:0046326 9.65 IGF1 PTH
15 ERK1 and ERK2 cascade GO:0070371 9.64 IGF1 TNFSF11
16 negative regulation of osteoclast differentiation GO:0045671 9.63 CALCA SFRP1
17 response to vitamin D GO:0033280 9.63 BGLAP PTH
18 bone mineralization GO:0030282 9.63 BGLAP BMP2 PTH
19 osteoblast development GO:0002076 9.62 BGLAP RUNX2
20 positive regulation of glycogen biosynthetic process GO:0045725 9.62 IGF1 PTH
21 regulation of osteoclast differentiation GO:0045670 9.61 BGLAP TNFSF11
22 positive regulation of ossification GO:0045778 9.6 BMP2 PTH
23 negative regulation of bone resorption GO:0045779 9.59 CALCA TNFRSF11B
24 response to inorganic substance GO:0010035 9.58 BGLAP TNFRSF11B
25 cellular response to vitamin D GO:0071305 9.58 BGLAP SFRP1
26 cellular response to BMP stimulus GO:0071773 9.58 BMP2 RUNX2 SFRP1
27 negative regulation of cardiac muscle cell differentiation GO:2000726 9.56 BMP2 DKK1
28 osteoblast differentiation GO:0001649 9.56 BGLAP BMP2 RUNX2 SFRP1
29 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.55 BMP2 RUNX2
30 ossification GO:0001503 9.55 ACP5 BGLAP BMP2 RUNX2 TNFSF11
31 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.54 BMP2 RUNX2
32 bone resorption GO:0045453 9.54 ACP5 PTH TNFSF11
33 bone mineralization involved in bone maturation GO:0035630 9.52 BMP2 IGF1
34 negative regulation of ossification GO:0030279 9.5 CALCA DKK1 SFRP1
35 regulation of signaling receptor activity GO:0010469 9.5 BMP2 CALCA DKK1 IGF1 PTH TNFRSF11B
36 Wnt signaling pathway involved in somitogenesis GO:0090244 9.48 DKK1 SFRP1
37 skeletal system development GO:0001501 9.1 BGLAP BMP2 IGF1 PTH RUNX2 TNFRSF11B
38 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 BMP2 IGF1 PTH RUNX2 TNFSF11

Molecular functions related to Glucocorticoid-Induced Osteoporosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 BMP2 TNFRSF11B TNFSF11
2 growth factor activity GO:0008083 9.33 BMP2 DKK1 IGF1
3 co-receptor binding GO:0039706 8.96 BMP2 DKK1
4 hormone activity GO:0005179 8.8 CALCA IGF1 PTH

Sources for Glucocorticoid-Induced Osteoporosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....